Additional file 1 of Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

Additional file 1: Table S1. List of primers sequences and their reaction conditions used in the present study. Table S2 List of antibodies used in the present study. Figure S1. Representative standard sequencing diagram for bisulfite direct sequencing of the TMEM240 gene. Figure S2 Copy number variation (CNV) analysis and chromosomal distribution of localized CNVs. (A) The workflow of CNV analysis. (B) CNV gain is shown as a red peak. (C) CNV loss is shown in the blue peak. Figure S3. The cell morphology was determined by microscopy in MDA-MB-231 cells (original magnification, ×100). Figure S4. Representative figures showing the TMEM240 mRNA expression by RNA sequencing in breast cancer patients from TCGA. Figure S5. Pathway Maps analysis of TMEM240 involvement in the epithelial–mesenchymal transition (EMT) process. MetaCore Pathway Maps analysis indicated that TMEM240 expression led to decreases in FGF2, NFkB, MMP2, and Oncostatin M and increases in E-cedherin and VE-cadherin. Figure S6. Pathway maps analysis of TMEM240 involvement in the SDF-1 pathway. MetaCore pathway maps analysis indicated that TMEM240 expression led to decreases in SDF-1, G-protein alpha-i2, and VAV-1 expression.